INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUS

Abstract

INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUS

Shelest B.O.

The problem of combined course of hypertension of diabetes mellitus type 2 and obesity is becoming more common. This variant of comorbidity crucially increases the risk of cardiovascular complications. Inflammation is considered as an important link between the progression of hypertension and the development of adverse events. This study is devoted to the question of the relationship between the pro-inflammatory marker interleukin-6 and the increased blood pressure in patients with concomitant diabetes and obesity. The treatment of such patients with combined pathology remains the actual and difficult issue of medical practice. The article analyses the dynamics of interleukin-6 in the process of treatment with a fixed triple antihypertensive combination.

 Key words: hypertension, interleukin-6, type 2 diabetes mellitus, obesity.

 

РІВНІ ІНТЕРЛЕЙКІНІВ У ХВОРИХ НА ГІПЕРТОНІЧНУ ХВОРОБУ У ПОЄДНАННІ З ЦУКРОВИМ ДІАБЕТОМ 2 ТИПУ 

Шелест Б.О.

Все більшого поширення набуває проблема поєднаного перебігу гіпертензії цукрового діабету 2 типу та ожиріння. Такий варіант коморбидности різко підвищує ризик кардіоваскулярних ускладнень. Важливою ланкою в прогресуванні гіпертензії і розвитку несприятливих подій відводиться запаленню. Дана робота присвячена питанню залежності прозапального маркера інтерлейкіну-6 і підвищених цифр артеріального тиску у хворих з супутнім цукровим діабетом 2 типу і ожирінням. Актуальним і складним питанням медичної практики залишається лікування таких пацієнтів з поєднаною патологією. У статті аналізується динаміка інтерлейкіну-6 в процесі лікування потрійною фіксованою антигіпертензивною комбінацією.

Ключові слова: гіпертонічна хвороба, інтерлейкін-6, цукровий діабет 2 типу, ожиріння.

 

УРОВЕНЬ ИНТЕРЛЕЙКИНОВ У ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА. 

Шелест Б.А.

Все большее распространение приобретает проблема сочетанного течения гипертензии сахарного диабета 2 типа и ожирения. Такой вариант коморбидности резко повышает риск кардиоваскулярных осложнений. Важным звеном в прогрессировании гипертензии и развитии неблагоприятных событий отводится воспалению. Даннаяработапосвящена вопросу зависимости провоспалительного маркера интерлейкина-6 и наличием повышенных цифр артериального давления у больных с сопутствующим сахарным диабетом и ожирением. Актуальным и сложным вопросом медицинской практики остается лечение таких пациентов с сочетанной патологией. В статье анализируется динамика интерлейкина-6 в процессе лечения фиксированной тройной антигипертензивной комбинацией. 

Ключевые слова: гипертоническая болезнь, интерлейкин-6, сахарный диабет 2 типа, ожирение.


https://doi.org/10.35339/ic.6.1.38-42
PDF

References

Shtygasheva O.V., Ageeva E.S., Iptyshev V.M. (2011). Rol' immunoreguljatornyh citokinov v patogeneze hronicheskogo gastrita i jazvennoj bolezni, poisk prediktorov zabolevanij [The role of immunoregulatory cytokines in the pathogenesis of chronic gastritis and peptic ulcer disease, the search for predictors of diseases]. Sibirskij medicinskij zhurnal, 1, 88­90.

Ketlinskiy, S.A., Simbirtsev A.S. (2008). Citokiny. [Cytokines]. SPB: “Foliant”, p. 408.

Galova E.A. (2008). Znachenie citokinov v patogeneze hronicheskogo gastroduodenita u detej doshkol'nogo vozrasta [Cytokines’ significance in the pathogenesis of chronic gastroduodenitis in preschool children]. Citokiny i vospalenie. 7, (1), 48­51

Zheleznjakova G.F. (2009). Citokiny kak prediktory techenija i ishoda infekcii [Cytokines as predictors of infection’s course and outcomes]. Citokiny i vospalenie, 8, (1), 10­17

Yan Q., Sun D., Li X., Chen G., Zheng Q., Li L., Gu C., Feng B. (2016). Association of blood glucose level and hypertension in Elderly Chinese Subjects: a community based study. BMC Endocr Disord, 16(1), 40

Cheung B.M., Li C. (2012). Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep, 14(2), 160-6.

Al-Shukaili A., Al-Ghafri S., Al-Marhoobi S., Al-Abri S., Al-Lawati J., Al-Maskari M. (2013). Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol, 2013, 976810

de Boer I.H., Bangalore S., Benetos A. (2017) Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care, 40, 1273

Svetlova M.S., Vezikova N.N., Romashina V.V. (2009). Ocenka soderzhanija s­rb, interlejkina­1 i ­6 i receptornogo antagonista interlejkina­1 v krovi bol'nyh rannim osteoartrozom kolennyh sustavov [Assessment of the C-RP, interleukin-1 and interleukin-6 and receptor antagonist interleukin-1 levels in patients with early osteoarthritis of the knee joints]. Terapevticheskij arhiv, 6, 52­56

Godbout J.P., Glaser R. (2006). Stress­Induced Immune Dysregulation: Implications for wound Healing, Infections Disease and Cancer. J. Neuroimmune Pharmacol, 1, (4), 421­427

Gadek­Michalska A., Bugajski A.J., Bugajski J. (2008). Prostaglandins and IL­1β in the hypothalamic­pituitary­adrenal response to systemic phenylephrine under basal. J. Physiol. Pharmacol, 59, (3), 563­575

Butkowski E.G., Brix L.M., Al-Aubaidy H.A., Kiat H., Jelinek H.J. (2016). Diabetes, oxidative stress and cardiovascular risk. J Med Clin Sci, 5(1), 17–23

Pouvreau C., Dayre A., Butkowski, E.G., de Jong B., Jelinek, H. F. (2018). Inflammation and oxidative stress markers in diabetes and hypertension. Journal of inflammation research, 11, 61-68

Lukic L., Lalic N.M., Rajkovic N., Jotic A., Lalic K., Milicic T., Seferovic J. P., Macesic, M., Gajovic J. S. (2014). Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: potential targets for an efficient preventive intervention. International journal of environmental research and public health, 11(4), 3586-98

Copyright for articles published in the journal is regulated by the License Agreement for the use of a scientific article in the journal, which is concluded between the author of the article (Licensor) and Kharkov National Medical University (Licensee, publisher of the journal "Inter Collegas"). The licensor grants to the Licensee a non-exclusive non-exclusive license for the use of the article (a license that does not exclude the use of the article by the Licensor and the issuance of licenses to others for use of this article) on the terms and for the period specified in the contract. The licensor (the author of the article) grants the Licensee the right to reproduce the article (publication in the journal "Inter Collegas", publication, duplication, duplication or other reproduction of the article without limiting the circulation of copies, each copy of the article must contain the name of the Licensor; Of general information, including the publication of the article in full or in part on the Internet on the journal page, the right to use the metadata of the article (titles, full names of authors, annotations, bibliography eskih materials) through the dissemination and communication to the public, processing and systematization, as well as inclusion in various databases and in-formational system).

The licensor grants the licensee the right to transfer, store and process his personal data (full name, scientific degree, academic title, place of work and position, contact information of the authors) with the purpose of including them in the database in accordance with the Law of Ukraine No. 2297 - VI "on protection of personal data" from 01.06.2010.

Personal data and metadata of the article are provided for their storage and processing in various databases and information systems, including them in analytical and statistical reporting, creating sound relationships between the objects of works of science, literature and art with personal data, etc. on unlimited territory. The licensee has the right to transfer the specified data for processing and storage to third parties provided that such a fact is notified with the provision of information about the third party (name and address) to the Licensor.